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Abstract 
Bovine respiratory disease continues to be the most important ailment of feedyard cattle.  
While the disease is multifactorial in nature, therapy continues to target the primary bacterial 
pathogens, Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.  A survey of 
records from a single diagnostic laboratory was conducted to evaluate the percentage of 
Mannheimia haemolytica isolates that were resistant to multiple antimicrobials and if co-
resistance patterns could be detected.  All susceptibility test results for Mannheimia haemolytica 
recovered from lung tissues of cattle were eligible for inclusion in the survey.  There were no 
isolates over the course of the analysis that were resistant to all 6 antimicrobials, primarily due to 
a lack of resistance to ceftiofur.  In 2009, just over 5% of isolates were resistant to 5 or more 
antimicrobials (pan-resistant).  In 2011, over 35% of the Mannheimia haemolytica isolates were 
characterized as pan-resistant.   Significant antimicrobial co-resistance patterns were only seen 
with oxytetracycline and tilmicosin; bacterial isolates that were resistant to either oxytetracycline 
or tilmicosin were more likely to be resistant to at least one other antimicrobial.  The 
mechanisms by which Mannheimia haemolytica is developing multi drug resistance warrant 
investigation if antimicrobial utility in the therapy of bovine respiratory disease is to be 
preserved. 
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Bovine respiratory disease (BRD) continues to be one of the most important diseases of 
feedlot cattle.20   The economic losses due to this disease have been estimated to approach $1 
billion dollars in the United States alone, due to increased drug and labor costs, decreased 
production and animal death losses.9  Applying this estimate today, however, does not account 
for the increasing pattern, and associated costs, of antimicrobial resistance among the BRD 
pathogens.16  While the exact cost of antimicrobial resistance in cases of BRD is unknown, this 
type of analysis in human cases has shown the economic impact of antimicrobial resistance to be 
significantly increased, both in terms of dollars and mortality.3,19   
It is not uncommon to find large scale summaries of susceptibility data for bovine 
bacterial pathogens.8,10,12,17,23   The data in these summaries are generally presented as either: 1) 
the percentage of isolates that are susceptible or resistant or 2) the MIC50 / MIC90 for the isolates 
tested.  While this information is useful for evaluating resistance of specific antimicrobials or 
antimicrobial classes, it does not allow for the evaluation of multi drug resistance for the 
individual isolates.  Data regarding the prevalence of multi drug antimicrobial resistance would 
clarify the role of susceptibility testing in BRD cases and would allow veterinary clinicians to 
design more effective empirical treatment protocols.   
The primary objective of the current retrospective analysis was to determine the 
prevalence of multi drug resistant Mannheimia haemolytica isolates from bovine respiratory 
disease cases.  The secondary objective was to determine if co-resistance was significantly 
associated with certain antimicrobials. 
All diagnostic records of the Kansas State Veterinary Diagnostic Laboratory from 
January 1, 2009 through December 31, 2011 were included in the initial search.  Records were 
included in the final analysis if they met the following criteria:  1) specimen was bovine lung; 2) 
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culture positive for Mannheimia haemolytica; 3) susceptibility test results were available; 4) 
isolate was from a clinical case (research isolates excluded). 
During the survey period, all susceptibility testing was performed using broth 
microdilution methods as recommended by Clinical and Laboratory Standards Institute (CLSI).6  
Briefly, growth from an overnight culture was used to directly suspend colonies into cation-
adjusted Mueller-Hinton broth.  Suspensions were adjusted to deliver approximately 5 x 105 
CFU/mL per well to the plates.a  Inoculation was performed using an automated delivery deviceb 
and plates were incubated for 18 to 24 hours in a 35°C, non-CO2 incubator.  In 2009 and 2010, 
plates were read using a manual system.c  In 2011, plates were read using a fully automated 
reading system.d 
  Only antimicrobials with CLSI approved interpretive criteria for Mannheimia 
haemolytica isolated from bovine respiratory disease were evaluated in this study.6  These 
antimicrobials included: ceftiofur, danofloxacin, enrofloxacin, florfenicol, oxytetracycline, 
spectinomycin, tilmicosin, and tulathromycin.  
Descriptive analysis was completed using a commercial spreadsheet program.e  Data 
analysis in the odds ratio portion was completed using a commercial statistical software 
program.f  Logistic regression (generalized mixed) models were used to analyze the probability 
that resistance to a given agent was associated with resistance to at least one other antimicrobial 
(co-resistance).  The random effect was animal-owner within year to reflect the lack of 
independence between samples.  A P-value of 0.10 was considered significant for all models.  
The search yielded 55, 155, and 179 eligible bacterial isolates from years 2009, 2010, and 
2011, respectively.  Following the initial analysis of 2011 data, strong relationships within drug 
class were noted for the fluoroquinolones and macrolides.  The susceptibility test results for 
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enrofloxacin and danofloxacin were equivalent within the error of the test (+/- 1 dilution) for 177 
of the 179 isolates.  For the macrolide class, the interpretation was “resistant” for both tilmicosin 
and tulathromycin in 153 of 179 (85.5%) isolates.  Of the remaining 26 isolates, 14 were 
interpretation discrepancies of “intermediate” and “susceptible”, which had no effect on the 
outcome variable of concern (“resistant”) in this report. Seven of the remaining isolates were 
“resistant” to tulathromycin and “intermediate” or “susceptible” to tilmicosin.  The remaining 5 
isolates were “resistant” to tilmicosin and “intermediate” or “susceptible” to tulathromycin.  To 
eliminate the antimicrobial class effect, danofloxacin and tulathromycin were excluded from the 
final analysis.  The class effect was not evaluated for 2009 and 2010 as the objective was to 
compare the same antimicrobials across the three year period. 
The contribution of isolates from individual premises was evaluated to control for bias in 
the data due to clonal isolates.  In this data set, the 389 isolates originated from 266 unique 
premises.  The majority of these premises (75.2%) are represented by only a single isolate in the 
three year data set (Fig. 2).  Less than 10% of the premises are represented by 3 or more isolates. 
The highest number of isolates from a single premise was nine (n=1).  Removing isolates from 
the same premise with identical susceptibility profiles in a given calendar year had minimal 
effects on the outcomes; 2011 isolates characterized as “resistant to 5 antimicrobials” would 
decrease by 3.75%, all other year-resistance classifications were affected by less than 2% (data 
not shown). No isolates were excluded from the data set because of their premise origin.  Doing 
so for these particular isolates had minimal effects on outcomes and represents an overly 
conservative approach to estimating multi drug resistance. 
Over the three year period, there were no bacterial isolates that were resistant to all 6 
antimicrobials.  This was primarily due to a general lack of resistance to ceftiofur.  Only 2 
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Mannheimia haemolytica isolates were classified as resistant to ceftiofur during the entire 
surveyed period (these isolates were susceptible to other antimicrobials).  In 2009, almost 35% of 
Mannheimia haemolytica isolates were susceptible to all 6 antimicrobials tested (pan-
susceptible).  Isolates resistant to 1, 2, 3, 4 and 5 antimicrobials made up 9%, 15%, 13%, 24% 
and 5% of recovered Mannheimia haemolytica, respectively.  In 2011, 17%, 8%, 12%, 3%, 25% 
and 35% of isolates were resistant to 0, 1, 2, 3, 4, and 5 antimicrobials, respectively.  (Fig. 1).  
Using resistance to 3 or more antimicrobials as the definition for multi drug resistance, 42%, 
46% and 63% of the isolates would be classified as multi drug resistant in 2009, 2010, and 2011, 
respectively. 
In determining co-resistance patterns, isolates found to be resistant to oxytetracycline 
were 3.52 times more likely (P = 0.04) to be resistant to one or more additional antimicrobials 
compared to non-oxytetracycline resistant isolates (Table 1).   Isolates resistant to tilmicosin 
were 2.64 times more likely (P = 0.06) to be resistant to at least one other antimicrobial (Table 
1).  There were no statistically significant co-resistance patterns for enrofloxin, florfenicol or 
spectinomycin over the three year period.  Due to low numbers of ceftiofur resistant isolates, the 
odds ratio was not calculated for this antimicrobial. 
Antimicrobial resistance in veterinary medicine has received a considerable amount of 
recognition as a potential factor leading to antimicrobial resistance in human medicine.1,2,22 
However, the contribution of multi drug resistance to limited or failed therapy in veterinary 
patients has received much less attention.15  Previous reports on multi drug resistance in 
Mannheimia haemolytica from cattle have been limited by low numbers (<30) of isolates or 
testing antimicrobials without CLSI approved interpretive criteria.4,5,7,18,24  A comprehensive 
study evaluating resistance in Mannheimia haemolytica reported very low rates (1.2%) of multi 
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drug resistance.13  In that study, isolates were obtained from the nasopharynx of cattle upon entry 
into and exit from 2 Canadian feedyards from September 2008 to February 2009.  The higher 
rates of multi drug resistance reported here could be a result of geographical and/or temporal 
factors.  These differences might also be explained by the methods used to select isolates; the 
Canadian study surveyed nasal flora of healthy animals, while the current study retrospectively 
analyzed isolates from lung tissue of deceased animals.   
The results of the current report indicate that a high percentage of Mannheimia 
haemolytica isolates recovered from bovine lung at the Kansas State Veterinary Diagnostic 
Laboratory are multi drug resistant.  Because there are a limited number of antimicrobial classes 
indicated for treatment of BRD and restrictions on the extra-label use of therapeutics in food 
animals, multi drug antimicrobial resistance in the BRD pathogens poses a severe threat to the 
livestock industry.   
The findings of the present study also emphasize the importance of antimicrobial 
susceptibility testing in the management of bovine respiratory disease.  In 2011, the majority 
(82.7%) of isolates were resistant to at least one antimicrobial.  Although ceftiofur was generally 
susceptible and oxytetracycline and tilmicosin were associated with co-resistance, the patterns of 
resistance to other antimicrobials were largely unpredictable.  Together, these factors would 
support the justification of susceptibility testing both from efficacy and antimicrobial 
stewardship standpoints.  The turnaround time of traditional culture and susceptibility testing 
makes it impractical for individual case management.  However, if used in early BRD cases, it 
can be useful for justifying treatment protocol deviations in future cases within the herd or group 
setting.   
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There are several limitations to the data summarized in this report.  As with all 
retrospective surveys of diagnostic submissions, the isolates selected for testing are not a random 
sample of all Mannheimia haemolytica isolates.11  As the isolates in this report are primarily 
from Kansas and Nebraska, there is the potential for geographical bias.  Similar retrospective 
analyses of human clinical isolates have shown strong regional distribution patterns of 
antimicrobial resistance phenotypes.21  The overrepresentation of feed yard submissions in these 
data likely reduce the external validity of the results to different cattle industry subgroups, but 
these limitations do not limit the importance of these findings, especially to feed yard 
veterinarians in the Midwest.  These data would support the need for similar analyses in other 
regions of the United States.    
In the current study, the selection criteria used (only isolates from lung tissue were 
included) creates a bias toward isolates causing clinical disease.  Although unknown in the 
majority of submissions, the assumption with regard to isolates from lung tissue is that the 
animal died from BRD.  The correlation between virulence of the bacterial organism and 
antimicrobial resistance phenotype is unknown, however isolates from clinical cases are more 
likely to have had previous exposure to antimicrobials.  Whether an animal had received prior 
antimicrobial treatments and/or the timing of therapy relative to death of the animal are potential 
confounding factors that are unknown in the majority of cases reported here.  Although the effect 
of prior treatment could not be evaluated here, it may be of minimal importance as a previous 
study reported that the antimicrobials used antemortem had little impact on the postmortem 
susceptibility patterns.14  While selection pressure from prior antimicrobial therapy may or may 
not impact the percentages of isolates reported here, the presence of these isolates cannot be 
dismissed.     
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Despite these limitations, this report provides a regional perspective on multi drug 
antimicrobial resistance in Mannheimia haemolytica isolates from cattle.  This survey was not 
designed to determine the clinical implications of multi drug resistance or the mechanisms by 
which these isolates are developing resistance.  However, these would be critical topics for 
further investigation if antimicrobial utility in food animals is to be preserved.  This study also 
highlights the need for continuing, prospective monitoring programs.   
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Tables	
Table 1.  Antimicrobial co‐resistance patterns of Mannheimia haemolytica isolates.   
Antimicrobial  Odds Ratio‡  95% Confidence Interval  P‐ Value 
Enrofloxacin   0.71  0.32 ‐ 1.58  0.41 
Florfenicol   1.43  0.63 ‐ 3.25  0.40 
Oxytetracycline   3.52  1.07 ‐ 11.61  0.04 
Spectinomycin   1.08  0.48 ‐ 2.44  0.86 
Tilmicosin  2.64  0.97 ‐ 7.17  0.06 
       
 
‡ Odds raƟo is the odds of an isolate being resistant to one or more other anƟmicrobials given 
resistance to the antimicrobial listed compared to the odds of an isolate being resistant to one or more 
other antimicrobials given the isolate is not resistant to the antimicrobial listed. 
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Figure	1	
 
 
Figure 1.  The percentage of Mannheimia haemolytica isolates, by year, which were resistant to 0, 1, 2, 
3, 4, and 5 antimicrobials, respectively.  Isolates in the 0 column would be considered pan susceptible 
isolates.  There were no isolates resistant to all 6 antimicrobials over the course of the survey. 
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Figure	2	
 
Figure 2.  The number of isolates recovered per premise during the 3 year survey period.  The 389 
Mannheimia haemolytica isolates originated from 266 unique premises.  The highest number of isolates 
recovered from a single premise was nine.   
